Project Grant R21AI180407
Award Date
6/1/24
Completion Date
4/30/26
Dollars Obligated
$233K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $383,750 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Nebraska Medical Center (UNMC) to discover novel antimicrobial peptides that can effectively eliminate drug-resistant gram-negative bacteria. The project aims to elucidate the structure-activity relationship, toxicity, pharmacokinetics, and in vivo efficacy of a novel antimicrobial peptide called Verine...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded Rowan University a $474,363 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop novel antimicrobial peptides inspired by the clinically approved compound daptomycin. The research aims to improve the understanding of sequence-structure-activity relationships and leverage non-canonical amino acids to create novel peptides that mimic daptomycin's key mechanisms of calcium...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Trustees of the Colorado School of Mines. The award, totaling $384,554, aims to develop novel drug candidates that target the SUF-like pathway of iron-sulfur cluster biosynthesis as a treatment for drug-resistant infections caused by Gram-positive bacteria such as Staphylococcus aureus, Enterococcus faecalis, and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $784,059 in funding to the University of North Carolina at Chapel Hill to investigate the newly discovered ability of the protein calprotectin to hydrolyze and inactivate certain beta-lactam antibiotics, such as ampicillin, amoxicillin, and oxacillin. The research will aim to determine the impact of calprotectin's...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $740,992 Project Grant to the Trustees of Indiana University, doing business as Indiana University, to develop an ex vivo skin wound infection model for studying Vibrio vulnificus pathogenesis. The research aims to assess the efficacy of thiophenesulfonamide compounds, such as PTSP, in preventing V. vulnificus colonization, decreasing...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $728,695 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Arkansas for Medical Sciences (UAMS) to study mechanisms of cefiderocol nonsusceptibility and resistance evolution in carbapenem-resistant pathogens. This 5-year grant will investigate preexisting cefiderocol resistance and heteroresistance in clinically isolated carbapenem-resistant gram-negative...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $300,000 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Singleto2 Therapeutics LLC, located in Summit, New Jersey. The project aims to develop and validate the efficacy of a superhydrophobic antimicrobial photodynamic therapy (SH-APDT) bandage for the prevention of multidrug-resistant burn wound infections. The SH-APDT bandage is designed to deliver airborne singlet oxygen,...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $443,175 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of North Carolina at Chapel Hill (UNC-CH) for a 2-year research project focused on understanding the molecular mechanisms underlying Clostridioides difficile colony dimorphism and its impact on virulence. The project aims to identify genes required for the formation of rough and smooth colony variants in C. difficile, and...
The University of North Carolina at Chapel Hill received a $521,030 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The funding supports a 5-year research project to define the interplay between stochastic and regulatory mechanisms underlying the heterogeneous expression of flagella and toxins in Clostridioides difficile. The research aims to provide mechanistic insights into...
This $405,015 Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) aims to investigate the mechanism of action of antibacterial synthetic unsaturated fatty acids against methicillin-resistant Staphylococcus aureus (MRSA).
The primary objectives are to determine if the synthetic unsaturated fatty acids 2-hexadecynoic acid (2-HDA) and DAT-51 can disrupt the cell membrane of MRSA through...